Stifel analyst Paul Matteis maintains $Neurogene (NGNE.US)$ with a buy rating, and maintains the target price at $46.
According to TipRanks data, the analyst has a success rate of 39.5% and a total average return of 2.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The valuation of Neurogene's shares is now closely aligned with its cash reserves following disclosures of a Serious Adverse Event in its NGN-401 high dose trial and the termination of the Battens program on November 11. Despite these setbacks, the company's management remains optimistic, not anticipating a clinical hold, as discussions with the FDA have suggested the safety of the low-dose option.
The firm revised its projections for third quarter 2024 earnings and incorporated the effects of a trial participant landing in critical condition following a high dose of NGN-401. This adjustment in analysis further influenced the expected market share for NGN-401 in the Rett syndrome gene therapy market, now estimated at 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
